Smartlab Europe

Intec Pharma Announces New Research Collaboration Agreement with MSD

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

UK Invests £47.8M to Expand NHS Clinical Trial Capacity

The UK government has announced nearly £50 million in...
- Advertisement -

Intec Pharma Ltd. announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential.

“We are very excited to continue to work with MSD,” said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “This new agreement builds upon the relationship we have enjoyed in prior research and allows the companies to leverage their combined experience in delivery.”

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.

Latest stories

Related stories

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

UK Invests £47.8M to Expand NHS Clinical Trial Capacity

The UK government has announced nearly £50 million in...

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »